Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk. Â This isÂ best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another companyÂ or by reviewing theÂ 5 Most Undervalued Companies for the Defensive Investor – July 2015.Â By using theÂ ModernGraham methodÂ one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries. Â What follows is a stock analysis showing a specific look at how Medtronic Inc. (MDT)Â fares in theÂ ModernGraham valuation model.
Company ProfileÂ (obtained fromÂ Google Finance): Medtronic Inc. (Medtronic) is a medical technology company. The Company offers its products to hospitals, physicians, clinicians and patients in over 140 countries. The Company operates in three segments: Cardiac and Vascular Group Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment manufactures and markets device-based medical therapies for Cardiac Rhythm Disease Management (CRDM) Coronary Structural Heart and Endovascular. The Restorative Therapies Group segment manufactures and markets device-based medical therapies for Spine Neuromodulation and Surgical Technologies. The Diabetes Group segment manufactures and markets device-based medical therapies for diabetes. The Company also offers Heli-FX and Heli-FX Thoracic EndoAnchor systems that feature an endovascular deployed anchor designed to attach various aortic endografts to the native vessel wall. It is also focused on the distribution of TourGuide Steerable Sheath in the United States and Europe.
To read the rest of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.
Defensive Investor – must pass at least 6 of the following 7 tests: Score = 6/7
- Adequate Size of Enterprise – market capitalization of at least $2 billion -Â PASS
- Sufficiently Strong Financial Condition – current ratio greater than 2 -Â PASS
- Earnings Stability – positive earnings per share for at least 10 straight years -Â PASS
- Dividend Record – has paid a dividend for at least 10 straight years -Â PASS
- Earnings Growth – earnings per share has increased by at least 1/3 over the last 10 years using 3 year averages at beginning and end of period -Â PASS
- Moderate PEmg ratio – PEmg is less than 20 -Â FAIL
- Moderate Price to Assets – PB ratio is less than 2.5 or PB x PEmg is less than 50 -Â PASS
Enterprising Investor – must pass at least 4Â of the following 5 tests or be suitable for a defensive investor: Score = 4/5
- Sufficiently Strong Financial Condition, Part 1 – current ratio greater than 1.5 -Â PASS
- Sufficiently Strong Financial Condition, Part 2 – Debt to Net Current Assets ratio less than 1.1 -Â FAIL
- Earnings Stability – positive earnings per share for at least 5 years -Â PASS
- Dividend Record – currently pays a dividend -Â PASS
- Earnings growth – EPSmg greater than 5 years ago -Â PASS
|Value Based on 3% Growth||$42.46|
|Value Based on 0% Growth||$24.89|
|Market Implied Growth Rate||8.88%|
|Net Current Asset Value (NCAV)||-$15.70|
Balance Sheet – AprilÂ 2015
Earnings Per Share
Earnings Per ShareÂ – ModernGraham
Medtronic Inc.Â qualifies for both the Defensive Investor and the Enterprising Investor. Â The Defensive Investor is only concerned with the high PEmg ratio. Â The Enterprising Investor is only concernedÂ with the level of debt relative to the net current assets. Â As a result, all valueÂ investorsÂ following the ModernGraham approach based on Benjamin Graham’s methods should feel comfortable proceeding with the evaluation. Â As for a valuation,Â the company appears to be overvalued afterÂ growingÂ itsÂ EPSmg (normalized earnings) from $2.49 in 2011 to an estimated $2.93 for 2015. Â This level of demonstrated earnings growth does not support the market’s implied estimate of 8.88% annual earnings growth over the next 7-10 years.Â As a result, the ModernGrahamÂ valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value belowÂ the price.
The next part of the analysis is up to individual investors, and requires discussion of the company’s prospects. Â What do you think? Â What value would you put on Medtronic Inc. (MDT)? Â Where do you see the company going in the future? Â Is there a company you like better? Â Leave aÂ comment on ourÂ Facebook pageÂ or mentionÂ @ModernGrahamÂ on Twitter to discuss.
Disclaimer: Â The author did not hold aÂ position in any company mentioned in this articleÂ at the time of publication and had no intention of changing that position within the next 72 hours. Â Logo taken from Wikipedia for the sole purpose of identifying the company; this article is not affiliated with the company in any manner.